Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside

Tyra Biosciences' average 12-month price target was lowered from $51.09 to $50.82 by 11 analysts, with forecasts ranging between $39 and $59. Based on the August 10 closing price, this implies a 94% upside potential. The consensus rating remains 'Buy', supported by 14 buy ratings, one hold, and no sell ratings among the 15 covering analysts.

According to estimates from 11 analysts, Tyra Biosciences, Inc. stock's average price target has fallen from $51.09 to $50.82, with forecasts ranging from $39 to $59 per share
Based on the Aug. 10 closing price, the updated target implies approximately 94% potential upside
Consensus rating remains at “Buy” across 15 covering analysts, with 14 Buys, 1 Holds and 0 Sells

Explore more price target data and ratings for Tyra Biosciences, Inc. on the , and track all previous and future analyst recommendations for Tyra Biosciences, Inc. in the dedicated News Flow.

Disclaimer

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.